Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s share price rose 7.6% during mid-day trading on Monday . The company traded as high as $28.28 and last traded at $27.12. Approximately 40,441 shares changed hands during trading, a decline of 93% from the average daily volume of 557,944 shares. The stock had previously closed at $25.21.
Analysts Set New Price Targets
Several equities research analysts have recently commented on MTSR shares. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target on the stock. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating on the stock.
View Our Latest Stock Analysis on Metsera
Metsera Trading Up 11.7 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- Canada Bond Market Holiday: How to Invest and Trade
- Super Micro’s International Presence Makes It a Winning Stock
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- Consumer Staples Stocks, Explained
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.